{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T09:04:49Z","timestamp":1791450289822,"version":"4.3.3"},"reference-count":117,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T00:00:00Z","timestamp":1692144000000},"content-version":"vor","delay-in-days":2784,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s13311-015-0391-5","type":"journal-article","created":{"date-parts":[[2015,9,23]],"date-time":"2015-09-23T13:21:52Z","timestamp":1443014512000},"page":"34-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":90,"title":["Efficacy of Intravenous Immunoglobulin in Neurological Diseases"],"prefix":"10.1016","volume":"13","author":[{"given":"Jan D.","family":"L\u00fcnemann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaak","family":"Quast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinos C.","family":"Dalakas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-015-0391-5_bib1","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0140-6736(81)92400-4","article-title":"High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood","volume":"1","author":"Imbach","year":"1981","journal-title":"Lancet"},{"key":"10.1007\/s13311-015-0391-5_bib2","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1056\/NEJM198205273062102","article-title":"Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin","volume":"306","author":"Fehr","year":"1982","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-015-0391-5_bib3","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1056\/NEJMra1009433","article-title":"Intravenous immune globulin in autoimmune and inflammatory diseases","volume":"367","author":"Gelfand","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-015-0391-5_bib4","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/nrneurol.2014.253","article-title":"Intravenous immunoglobulin in neurology\u2013mode of action and clinical efficacy","volume":"11","author":"Lunemann","year":"2015","journal-title":"Nat Rev Neurol"},{"key":"10.1007\/s13311-015-0391-5_bib5","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1172\/JCI24772","article-title":"Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions","volume":"115","author":"Boruchov","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1007\/s13311-015-0391-5_bib6","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1084\/jem.189.1.187","article-title":"Deletion of fcgamma receptor IIB renders H-2(b) mice susceptible to collagen-induced arthritis","volume":"189","author":"Yuasa","year":"1999","journal-title":"J Exp Med"},{"key":"10.1007\/s13311-015-0391-5_bib7","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/1074-7613(95)90134-5","article-title":"The same tyrosine-based inhibition motif, in the intracytoplasmic domain of Fc gamma RIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation","volume":"3","author":"Daeron","year":"1995","journal-title":"Immunity"},{"key":"10.1007\/s13311-015-0391-5_bib8","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/ni1440","article-title":"FcgammaRIIb controls bone marrow plasma cell persistence and apoptosis","volume":"8","author":"Xiang","year":"2007","journal-title":"Nat Immunol"},{"key":"10.1007\/s13311-015-0391-5_bib9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/ni1151","article-title":"The inhibitory Fcgamma receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+ anti-DNA plasma cells","volume":"6","author":"Fukuyama","year":"2005","journal-title":"Nat Immunol"},{"key":"10.1007\/s13311-015-0391-5_bib10","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.4049\/jimmunol.172.4.2021","article-title":"Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn","volume":"172","author":"Ober","year":"2004","journal-title":"J Immunol"},{"key":"10.1007\/s13311-015-0391-5_bib11","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1084\/jem.20021829","article-title":"The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan","volume":"197","author":"Chaudhury","year":"2003","journal-title":"J Exp Med"},{"key":"10.1007\/s13311-015-0391-5_bib12","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1172\/JCI6968","article-title":"Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line","volume":"104","author":"Dickinson","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1007\/s13311-015-0391-5_bib13","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/science.282.5388.490","article-title":"Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin","volume":"282","author":"Viard","year":"1998","journal-title":"Science"},{"key":"10.1007\/s13311-015-0391-5_bib14","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.4049\/jimmunol.143.12.4104","article-title":"Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig","volume":"143","author":"Rossi","year":"1989","journal-title":"J Immunol"},{"key":"10.1007\/s13311-015-0391-5_bib15","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/intimm\/dxf099","article-title":"Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus","volume":"14","author":"Shoenfeld","year":"2002","journal-title":"Int Immunol"},{"key":"10.1007\/s13311-015-0391-5_bib16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jneuroim.2007.11.020","article-title":"A disease-specific fraction isolated from IVIG is essential for the immunosuppressive effect of IVIG in experimental autoimmune myasthenia gravis","volume":"194","author":"Fuchs","year":"2008","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-015-0391-5_bib17","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/ana.10205","article-title":"Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barr\u00e9 syndrome","volume":"51","author":"Buchwald","year":"2002","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-015-0391-5_bib18","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1073\/pnas.89.8.3325","article-title":"Human autoantibodies reactive with synthetic autoantigens from T-cell receptor beta chain","volume":"89","author":"Marchalonis","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-015-0391-5_bib19","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/0140-6736(93)92000-J","article-title":"Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura","volume":"342","author":"Debre","year":"1993","journal-title":"Lancet"},{"key":"10.1007\/s13311-015-0391-5_bib20","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1182\/blood-2014-05-576835","article-title":"Inhibition of FcgammaR-mediated phagocytosis by IVIg is independent of IgG-Fc sialylation and FcgammaRIIb in human macrophages","volume":"124","author":"Nagelkerke","year":"2014","journal-title":"Blood"},{"key":"10.1007\/s13311-015-0391-5_bib21","doi-asserted-by":"crossref","first-page":"4788","DOI":"10.1073\/pnas.0807319106","article-title":"Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy","volume":"106","author":"Tackenberg","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-015-0391-5_bib22","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1126\/science.291.5503.484","article-title":"Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor","volume":"291","author":"Samuelsson","year":"2001","journal-title":"Science"},{"key":"10.1007\/s13311-015-0391-5_bib23","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1055\/s-0037-1613331","article-title":"Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor","volume":"88","author":"Hansen","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1007\/s13311-015-0391-5_bib24","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1365-3083.1994.tb03430.x","article-title":"Intravenous immunoglobulins suppress immunoglobulin productions by suppressing Ca(2+)-dependent signal transduction through Fc gamma receptors in B lymphocytes","volume":"40","author":"Kondo","year":"1994","journal-title":"Scand J Immunol"},{"key":"10.1007\/s13311-015-0391-5_bib25","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature10134","article-title":"Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway","volume":"475","author":"Anthony","year":"2011","journal-title":"Nature"},{"key":"10.1007\/s13311-015-0391-5_bib26","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1365-3083.1995.tb03591.x","article-title":"Inhibition of complement-mediated red cell lysis by immunoglobulins is dependent on the IG isotype and its C1 binding properties","volume":"41","author":"Mollnes","year":"1995","journal-title":"Scand J Immunol"},{"key":"10.1007\/s13311-015-0391-5_bib27","doi-asserted-by":"crossref","unstructured":"Quast I, Keller CW, Maurer MA, Giddens JP, Tackenberg B, Wang LX, M\u00fcnz C, Nimmerjahn F, Dalakas MC, L\u00fcnemann JD. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity. J Clin Invest 2015; in press.","DOI":"10.1172\/JCI82695"},{"key":"10.1007\/s13311-015-0391-5_bib28","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1182\/blood-2008-02-138073","article-title":"Activation of natural regulatory T cells by IgG Fc-derived peptide \u201cTregitopes\u201d","volume":"112","author":"De Groot","year":"2008","journal-title":"Blood"},{"key":"10.1007\/s13311-015-0391-5_bib29","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood-2002-05-1447","article-title":"Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin","volume":"101","author":"Bayry","year":"2003","journal-title":"Blood"},{"key":"10.1007\/s13311-015-0391-5_bib30","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1126\/science.1129594","article-title":"Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation","volume":"313","author":"Kaneko","year":"2006","journal-title":"Science"},{"key":"10.1007\/s13311-015-0391-5_bib31","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1126\/science.1154315","article-title":"Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc","volume":"320","author":"Anthony","year":"2008","journal-title":"Science"},{"key":"10.1007\/s13311-015-0391-5_bib32","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/eji.201344230","article-title":"Broad requirement for terminal sialic acid residues and FcgammaRIIB for the preventive and therapeutic activity of intravenous immunoglobulins in vivo","volume":"44","author":"Schwab","year":"2014","journal-title":"Eur J Immunol"},{"key":"10.1007\/s13311-015-0391-5_bib33","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1111\/j.1537-2995.2011.03517.x","article-title":"Sialylation-independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin","volume":"52","author":"Leontyev","year":"2012","journal-title":"Transfusion"},{"key":"10.1007\/s13311-015-0391-5_bib34","doi-asserted-by":"crossref","first-page":"5261","DOI":"10.1182\/blood-2012-03-415695","article-title":"Mouse background and IVIG dosage are critical in establishing the role of inhibitory Fcgamma receptor for the amelioration of experimental ITP","volume":"119","author":"Leontyev","year":"2012","journal-title":"Blood"},{"key":"10.1007\/s13311-015-0391-5_bib35","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1002\/eji.201444440","article-title":"Sialylation may be dispensable for reciprocal modulation of helper T cells by intravenous immunoglobulin","volume":"44","author":"Othy","year":"2014","journal-title":"Eur J Immunol"},{"key":"10.1007\/s13311-015-0391-5_bib36","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrneurol.2011.121","article-title":"Advances in the diagnosis, pathogenesis and treatment of CIDP","volume":"7","author":"Dalakas","year":"2011","journal-title":"Nat Rev Neurol"},{"key":"10.1007\/s13311-015-0391-5_bib37","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJM199204233261705","article-title":"A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain\u2013Barr\u00e9 syndrome. Dutch Guillain-Barr\u00e9 Study Group","volume":"326","author":"van der Meche","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-015-0391-5_bib38","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0140-6736(96)09095-2","article-title":"Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barr\u00e9 syndrome","volume":"349","author":"Plasma Exchange\/Sandoglobulin Guillain-Barr\u00e9 Syndrome Trial Group","year":"1997","journal-title":"Lancet"},{"key":"10.1007\/s13311-015-0391-5_bib39","doi-asserted-by":"crossref","first-page":"R164","DOI":"10.1186\/cc10305","article-title":"Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barr\u00e9 syndrome: a randomized study","volume":"15","author":"El-Bayoumi","year":"2011","journal-title":"Crit Care"},{"key":"10.1007\/s13311-015-0391-5_bib40","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(97)24050-X","article-title":"Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain-Barr\u00e9 syndrome","volume":"350","author":"Farcas","year":"1997","journal-title":"Lancet"},{"key":"10.1007\/s13311-015-0391-5_bib41","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/ana.21737","article-title":"Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barr\u00e9 syndrome","volume":"66","author":"Kuitwaard","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-015-0391-5_bib42","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/ana.1088","article-title":"Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"50","author":"Hughes","year":"2001","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-015-0391-5_bib43","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/ana.410360607","article-title":"A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"36","author":"Dyck","year":"1994","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-015-0391-5_bib44","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1212\/WNL.56.4.445","article-title":"Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy","volume":"56","author":"Mendell","year":"2001","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0391-5_bib45","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","article-title":"Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial","volume":"7","author":"Hughes","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-015-0391-5_bib46","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1212\/WNL.0b013e3181a0fd80","article-title":"Health-related quality-of-life improvements in CIDP with immune globulin IV 10%: the ICE Study","volume":"72","author":"Merkies","year":"2009","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0391-5_bib47","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mus.21236","article-title":"Electrophysiology in chronic inflammatory demyelinating polyneuropathy with IGIV","volume":"39","author":"Bril","year":"2009","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-015-0391-5_bib48","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1001\/archneurol.2010.105","article-title":"Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"67","author":"Latov","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-015-0391-5_bib49","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/jnnp.56.1.36","article-title":"Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study","volume":"56","author":"Vermeulen","year":"1993","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-015-0391-5_bib50","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/brain\/119.4.1055","article-title":"Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study","volume":"119","author":"Hahn","year":"1996","journal-title":"Brain"},{"key":"10.1007\/s13311-015-0391-5_bib51","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1212\/WNL.0b013e3181bd1139","article-title":"Single nucleotide polymorphism of TAG-1 influences IVIg responsiveness of Japanese patients with CIDP","volume":"73","author":"Iijima","year":"2009","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0391-5_bib52","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/ana.410330303","article-title":"Multifocal motor neuropathy: response to human immune globulin","volume":"33","author":"Chaudhry","year":"1993","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-015-0391-5_bib53","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1212\/WNL.55.9.1256","article-title":"Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study","volume":"55","author":"Federico","year":"2000","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0391-5_bib54","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1093\/brain\/awf193","article-title":"Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment","volume":"125","author":"Van den Berg-Vos","year":"2002","journal-title":"Brain"},{"key":"10.1007\/s13311-015-0391-5_bib55","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ana.410400516","article-title":"A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy","volume":"40","author":"Dalakas","year":"1996","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-015-0391-5_bib56","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1007\/s00415-002-0808-z","article-title":"A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy","volume":"249","author":"Comi","year":"2002","journal-title":"J Neurol"},{"key":"10.1007\/s13311-015-0391-5_bib57","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/jnnp.2008.149013","article-title":"Intravenous immunoglobulin is effective in patients with diabetes and with chronic inflammatory demyelinating polyneuropathy: long term follow-up","volume":"80","author":"Jann","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-015-0391-5_bib58","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jocn.2009.12.013","article-title":"Differential response to intravenous immunoglobulin (IVIg) therapy among multifocal and polyneuropathy types of painful diabetic neuropathy","volume":"17","author":"Kawagashira","year":"2010","journal-title":"J Clin Neurosci"},{"key":"10.1007\/s13311-015-0391-5_bib59","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1196\/annals.1361.121","article-title":"Response of vasculitic peripheral neuropathy to intravenous immunoglobulin","volume":"1051","author":"Levy","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"10.1007\/s13311-015-0391-5_bib60","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/acr.20495","article-title":"Experience of intravenous immunoglobulin therapy in neuropathy associated with primary Sjogren's syndrome: a national multicentric retrospective study","volume":"63","author":"Rist","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1007\/s13311-015-0391-5_bib61","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ana.410410615","article-title":"Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group","volume":"41","author":"Gajdos","year":"1997","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-015-0391-5_bib62","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1001\/archneur.62.11.1689","article-title":"Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial","volume":"62","author":"Gajdos","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-015-0391-5_bib63","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1212\/01.wnl.0000256698.69121.45","article-title":"IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial","volume":"68","author":"Zinman","year":"2007","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0391-5_bib64","doi-asserted-by":"crossref","unstructured":"Gajdos P, Chevret S, Toyka K. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 2008;CD002277.","DOI":"10.1002\/14651858.CD002277.pub3"},{"key":"10.1007\/s13311-015-0391-5_bib65","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1212\/WNL.47.3.678","article-title":"Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert\u2013Eaton myasthenic syndrome","volume":"47","author":"Bain","year":"1996","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0391-5_bib66","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-015-0391-5_bib67","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1172\/JCI117520","article-title":"High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments","volume":"94","author":"Basta","year":"1994","journal-title":"J Clin Invest"},{"issue":"6 Suppl. 5","key":"10.1007\/s13311-015-0391-5_bib68","first-page":"S37","article-title":"Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis","volume":"51","author":"Dalakas","year":"1998","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0391-5_bib69","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1006\/clim.1999.4823","article-title":"Downregulation of TGF-beta1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin","volume":"94","author":"Amemiya","year":"2000","journal-title":"Clin Immunol"},{"key":"10.1007\/s13311-015-0391-5_bib70","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1093\/brain\/awh518","article-title":"Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes","volume":"128","author":"Raju","year":"2005","journal-title":"Brain"},{"key":"10.1007\/s13311-015-0391-5_bib71","first-page":"397","article-title":"The effect of intravenous immunoglobulin (IVIG) treatment on patients with dermatomyositis: a 4-year follow-up study","volume":"30","author":"Kampylafka","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1007\/s13311-015-0391-5_bib72","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s10067-012-1940-5","article-title":"Intravenous immunoglobulin therapy in adult patients with polymyositis\/dermatomyositis: a systematic literature review","volume":"31","author":"Wang","year":"2012","journal-title":"Clin Rheumatol"},{"key":"10.1007\/s13311-015-0391-5_bib73","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/WNL.48.3.712","article-title":"Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study","volume":"48","author":"Dalakas","year":"1997","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0391-5_bib74","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s004150050005","article-title":"High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study","volume":"247","author":"Walter","year":"2000","journal-title":"J Neurol"},{"key":"10.1007\/s13311-015-0391-5_bib75","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1212\/WNL.56.3.323","article-title":"A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM","volume":"56","author":"Dalakas","year":"2001","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0391-5_bib76","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1002\/art.37692","article-title":"Provision of an explanation for the inefficacy of immunotherapy in sporadic inclusion body myositis: quantitative assessment of inflammation and beta-amyloid in the muscle","volume":"64","author":"Zschuntzsch","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1007\/s13311-015-0391-5_bib77","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1212\/WNL.55.10.1531","article-title":"The clinical spectrum of anti-GAD antibody-positive patients with stiff-person syndrome","volume":"55","author":"Dalakas","year":"2000","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0391-5_bib78","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa01167","article-title":"High-dose intravenous immune globulin for stiff-person syndrome","volume":"345","author":"Dalakas","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-015-0391-5_bib79","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0140-6736(96)09377-4","article-title":"Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group","volume":"349","author":"Fazekas","year":"1997","journal-title":"Lancet"},{"key":"10.1007\/s13311-015-0391-5_bib80","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1212\/WNL.50.2.398","article-title":"Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses","volume":"50","author":"Achiron","year":"1998","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0391-5_bib81","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1212\/01.WNL.0000145798.61383.39","article-title":"IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS","volume":"63","author":"Sorensen","year":"2004","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0391-5_bib82","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1191\/1352458504ms978sr","article-title":"A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS","volume":"10","author":"Visser","year":"2004","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-015-0391-5_bib83","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1212\/01.wnl.0000318281.98220.6f","article-title":"Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial","volume":"71","author":"Fazekas","year":"2008","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0391-5_bib84","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(04)17101-8","article-title":"Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial","volume":"364","author":"Hommes","year":"2004","journal-title":"Lancet"},{"key":"10.1007\/s13311-015-0391-5_bib85","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00415-004-0495-z","article-title":"Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis","volume":"251","author":"Achiron","year":"2004","journal-title":"J Neurol"},{"key":"10.1007\/s13311-015-0391-5_bib86","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1177\/1352458506075654","article-title":"A dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis","volume":"13","author":"Haas","year":"2007","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-015-0391-5_bib87","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/1352458513495938","article-title":"Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients","volume":"20","author":"Elsone","year":"2014","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-015-0391-5_bib88","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.nrl.2012.03.014","article-title":"The effect of intravenous immunoglobulin on neuromyelitis optica","volume":"28","author":"Magraner","year":"2013","journal-title":"Neurologia"},{"key":"10.1007\/s13311-015-0391-5_bib89","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","article-title":"Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study","volume":"12","author":"Titulaer","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-015-0391-5_bib90","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1749-6632.1995.tb27543.x","article-title":"Pathogenetic mechanisms of post-polio syndrome: morphological, electrophysiological, virological, and immunological correlations","volume":"753","author":"Dalakas","year":"1995","journal-title":"Ann N Y Acad Sci"},{"key":"10.1007\/s13311-015-0391-5_bib91","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1474-4422(06)70447-1","article-title":"Intravenous immunoglobulin for post-polio syndrome: a randomised controlled trial","volume":"5","author":"Gonzalez","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-015-0391-5_bib92","doi-asserted-by":"crossref","first-page":"152","DOI":"10.7326\/0003-4819-152-3-201002020-00006","article-title":"Intravenous immunoglobulin treatment of the complex regional pain syndrome: a randomized trial","volume":"152","author":"Goebel","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1007\/s13311-015-0391-5_bib93","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1111\/ene.12513","article-title":"Subcutaneous immunoglobulin preserves muscle strength in chronic inflammatory demyelinating polyneuropathy","volume":"21","author":"Markvardsen","year":"2014","journal-title":"Eur J Neurol"},{"key":"10.1007\/s13311-015-0391-5_bib94","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1136\/jnnp-2013-306227","article-title":"Pharmacokinetics of intravenous immunoglobulin in multifocal motor neuropathy","volume":"85","author":"Vlam","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-015-0391-5_bib95","doi-asserted-by":"crossref","first-page":"259","DOI":"10.7326\/0003-4819-121-4-199408150-00004","article-title":"Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors","volume":"121","author":"Sekul","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1007\/s13311-015-0391-5_bib96","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/mus.24526","article-title":"Optimizing IgG therapy in chronic autoimmune neuropathies: a hypothesis driven approach","volume":"51","author":"Berger","year":"2015","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-015-0391-5_bib97","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1007\/s13311-015-0391-5_bib98","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1056\/NEJM199901213400311","article-title":"Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases","volume":"340","author":"Yu","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-015-0391-5_bib99","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/ACI.0b013e32834c22da","article-title":"Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose","volume":"11","author":"Berger","year":"2011","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1007\/s13311-015-0391-5_bib100","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.clim.2011.01.006","article-title":"Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies","volume":"139","author":"Berger","year":"2011","journal-title":"Clin Immunol"},{"key":"10.1007\/s13311-015-0391-5_bib101","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1212\/WNL.0b013e31824de293","article-title":"Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"78","author":"Patwa","year":"2012","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0391-5_bib102","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0140-6736(86)92511-0","article-title":"Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients","volume":"2","author":"Woodruff","year":"1986","journal-title":"Lancet"},{"key":"10.1007\/s13311-015-0391-5_bib103","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/BF02076702","article-title":"Hyperviscosity in HIV infected children\u2013a potential hazard during intravenous immunoglobulin therapy","volume":"61","author":"Hague","year":"1990","journal-title":"Blut"},{"key":"10.1007\/s13311-015-0391-5_bib104","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1399-3038.1994.tb00230.x","article-title":"Intravenous gammaglobulin, 2: Pharmacology, clinical uses and mechanisms of action","volume":"5","author":"Schiff","year":"1994","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1007\/s13311-015-0391-5_bib105","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1399-3038.1994.tb00222.x","article-title":"Intravenous gammaglobulin: pharmacology, clinical uses and mechanisms of action","volume":"5","author":"Schiff","year":"1994","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1007\/s13311-015-0391-5_bib106","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1212\/WNL.44.2.223","article-title":"High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events","volume":"44","author":"Dalakas","year":"1994","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0391-5_bib107","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1212\/01.WNL.0000074394.15882.83","article-title":"Strokes, thromboembolic events, and IVIg: rare incidents blemish an excellent safety record","volume":"60","author":"Dalakas","year":"2003","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0391-5_bib108","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/WNL.46.1.250","article-title":"Reversible encephalopathy with cerebral vasospasm in a Guillain-Barr\u00e9 syndrome patient treated with intravenous immunoglobulin","volume":"46","author":"Voltz","year":"1996","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0391-5_bib109","doi-asserted-by":"crossref","first-page":"721","DOI":"10.7326\/0003-4819-126-9-199705010-00008","article-title":"Intravenous immune globulin therapy for neurologic diseases","volume":"126","author":"Dalakas","year":"1997","journal-title":"Ann Intern Med"},{"issue":"6 Suppl.","key":"10.1007\/s13311-015-0391-5_bib110","doi-asserted-by":"crossref","first-page":"70S","DOI":"10.1007\/BF01540896","article-title":"Update on the use of intravenous immune globulin in the treatment of patients with inflammatory muscle disease","volume":"15","author":"Dalakas","year":"1995","journal-title":"J Clin Immunol"},{"key":"10.1007\/s13311-015-0391-5_bib111","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/(SICI)1097-4598(199911)22:11<1479::AID-MUS3>3.0.CO;2-B","article-title":"Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines","volume":"22","author":"Dalakas","year":"1999","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-015-0391-5_bib112","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/BF00915419","article-title":"Immunoglobulin prophylaxis in patients with antibody deficiency syndromes and anti-IgA antibodies","volume":"7","author":"Bjorkander","year":"1987","journal-title":"J Clin Immunol"},{"key":"10.1007\/s13311-015-0391-5_bib113","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1056\/NEJM198602273140907","article-title":"Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA","volume":"314","author":"Burks","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-015-0391-5_bib114","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1002\/(SICI)1097-4598(199709)20:9<1102::AID-MUS2>3.0.CO;2-C","article-title":"Effect of high-dose intravenous immunoglobulin on serum chemistry, hematology, and lymphocyte subpopulations: assessments based on controlled treatment trials in patients with neurological diseases","volume":"20","author":"Koffman","year":"1997","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-015-0391-5_bib115","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1046\/j.1351-5101.2003.00701.x","article-title":"Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"10","author":"McCrone","year":"2003","journal-title":"Eur J Neurol"},{"key":"10.1007\/s13311-015-0391-5_bib116","doi-asserted-by":"crossref","unstructured":"Quast I, Cueni F, Nimmerjahn F, Tackenberg B, Lunemann JD. Deregulated Fc\u03b3 Receptor Expression in Patients with CIDP. Neurol Neuroimmunol Neuroinflamm 2015; in press.","DOI":"10.1212\/NXI.0000000000000148"},{"key":"10.1007\/s13311-015-0391-5_bib117","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/nri3401","article-title":"Intravenous immunoglobulin therapy: how does IgG modulate the immune system?","volume":"13","author":"Schwab","year":"2013","journal-title":"Nat Rev Immunol"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-015-0391-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-015-0391-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923009376?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923009376?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-015-0391-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:49:47Z","timestamp":1761806987000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923009376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":117,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S1878747923009376"],"URL":"https:\/\/doi.org\/10.1007\/s13311-015-0391-5","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of Intravenous Immunoglobulin in Neurological Diseases","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-015-0391-5","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}